Clinical Trial Update: Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy [Phase 1]

View source ↗

Summary

Phase 1 safety study of a Cytotoxic Lymphocytes (CTL)–based therapy for castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy

Snippet

Sponsor: CytoVac A/S | Conditions: Hormone-refractory Prostate Cancer | Phase 1 | Status: COMPLETED